None listed
Conditions
Interventions
Radiation : The HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein) will be included in this study. Total stereotactic ablative
Sponsors
Korea Institute of Radiological & Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female patients =18 years of age 2. Eastern Cooerative Oncology Group performance status 0 or 1 3. HCC with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein) 4. Cirrhotic status of Child Pugh class A or B7 5. Patients can have extra-hepatic disease; provided the hepatic disease is the highest burden, the extra-hepatic disease is low burden and potentially treatable with radiotherapy, chemotherapy and target agent etc; patient survival is expected to be at least 6 months. 6. Patient or gaurdian must be able to provide verbal and written informed consent
Exclusion criteria
Exclusion criteria: 1. Prior trans-arterial chemo-embolization =4 after diagnosis of major portal vein tumor thrombosis 2. Severe complication caused by liver cirrhosis eg. variceal bleeding, poorly controlled ascites, hepatic encephalopathy) 3. Uncontrolled inter-current illness except liver cirrhosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor stabilization rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Tumor progression free survival;Treatment related toxicity | — |
Countries
Korea, Republic of
Contacts
Public ContactSun Hyun Bae
Korea Institute of Radiological & Medical Sciences
Outcome results
None listed